Review Article

Tunneling Nanotubes and the Eye: Intercellular Communication and Implications for Ocular Health and Disease

Holly R. Chinnery and Kate E. Keller

1Department of Optometry and Vision Sciences, The University of Melbourne, Monash Road, Parkville 3010, Australia
2Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, USA 97239

Correspondence should be addressed to Kate E. Keller; gregorka@ohsu.edu

Received 5 February 2020; Accepted 10 March 2020; Published 9 April 2020

Academic Editor: Michela Ori

Cellular communication is an essential process for the development and maintenance of all tissues including the eye. Recently, a new method of cellular communication has been described, which relies on formation of tubules, called tunneling nanotubes (TNTs). These structures connect the cytoplasm of adjacent cells and allow the direct transport of cellular cargo between cells without the need for secretion into the extracellular milieu. TNTs may be an important mechanism for signaling between cells that reside long distances from each other or for cells in aqueous environments, where diffusion-based signaling is challenging.

Given the wide range of cargoes transported, such as lysosomes, endosomes, mitochondria, viruses, and miRNAs, TNTs may play a role in normal homeostatic processes in the eye as well as function in ocular disease. This review will describe TNT cellular communication in ocular cell cultures and the mammalian eye in vivo, the role of TNTs in mitochondrial transport with an emphasis on mitochondrial eye diseases, and molecules involved in TNT biogenesis and their function in eyes, and finally, we will describe TNT formation in inflammation, cancer, and stem cells, focusing on pathological processes of particular interest to vision scientists.

1. Introduction

Cells have numerous mechanisms of communication in order to develop normally, repair wounds, and respond to inflammation. Many of these mechanisms rely on secretion of signals from one cell, diffusion through the extracellular milieu, and uptake by a target cell, which may be located far from the secretory cell. An excellent synopsis of morphogen signaling was recently published, which uses a “drunken sailor” analogy to comprehensively describe the current models, hypotheses, and challenges of diffusion-based signaling processes (Figure 1) [1]. Two more recent modes of communication are also described: cytonemes and tunneling nanotubes (TNTs) (Figure 2). These cellular structures allow signaling over long distances by providing direct connections between cells, which overcomes many challenges of diffusion-based signaling [2–7]. While cytonemes have been described in the Drosophila imaginal eye disc [8], nothing is known of their existence in the vertebrate eye. Conversely, there is a burgeoning literature on TNTs since their first description in 2004 [2]. TNTs are specialized filopodia that transport signals directly between cells. TNTs are composed of an actin core, although microtubules may also be involved in certain cell types [9]. Due to continuity of cytoplasm within the tube, larger cargo can be trafficked than could be shared via gap junctions [10–14]. LysoTracker-labeled vesicles were the first organelles shown to be transported from one cell to an adjacent one [2]. Other groups subsequently showed the intercellular transfer of mitochondria and endocytic vesicles derived from early endosomes, the Golgi complex, endoplasmic reticulum, and lysosomes [15–20]. In addition, TNTs are involved in the spread of pathogens such as viruses, prions, and bacteria [12, 18, 21–23] and other small molecules such as miRNAs, Ca^{2+}, calcine, Lucifer yellow, and quantum dot nanoparticles [11, 24–29]. However, there appears to be some selectivity in the cargo that is
This review will detail the current knowledge of the existence and potential role of TNTs in ocular homeostasis and disease pathogenesis. We will first describe (1) the current knowledge of TNTs in the mammalian eye, (2) the role of TNTs in mitochondrial transfer with an emphasis on eye disease, (3) TNT molecular regulators and their function in eyes, and (4) the role of TNTs in other diseases that are of interest to vision researchers.

2. TNTs and Cytonemes in the Eye

2.1. TNTs in Corneal Tissue. A few years following the initial reports of TNTs in in vitro settings, Chinnery et al. described the presence of long (up to 300 microns), thin (<1 micron) membrane extensions protruding from MHC Class II-positive immune cells in the mouse cornea (Figure 3) [40].

transferred because some TNTs support transfer of electrical signals, while other cell types do not [10, 30]. Thus, TNTs may be responsible for communicating cellular signals that previously were thought to have been mediated by diffusion.

There are several excellent reviews that provide in-depth discussion on TNT biogenesis [11, 19, 30, 31]. Two current biogenesis models are the cell dislodgement and the actin-driven models [2, 3, 25]. In the former, two adjacent cells in close proximity form short tubes, which are drawn out as the cells move apart. In the actin-driven model, filopodia extend from two adjacent cells and when their tips touch, they fuse to form a single conduit. As the name implies, this latter mechanism depends on actin. Several molecules are also implicated in TNT formation, including M-Sec, myosin-Va, myosin-X, synaptophysin, Rho GTPases (cdc42, Rac1), RASSF1A, LST1, and Rab8/Rab11a [25, 32–39].

transferred because some TNTs support transfer of electrical signals, while other cell types do not [10, 30]. Thus, TNTs may be responsible for communicating cellular signals that previously were thought to have been mediated by diffusion.

There are several excellent reviews that provide in-depth discussion on TNT biogenesis [11, 19, 30, 31]. Two current biogenesis models are the cell dislodgement and the actin-driven models [2, 3, 25]. In the former, two adjacent cells in close proximity form short tubes, which are drawn out as the cells move apart. In the actin-driven model, filopodia extend from two adjacent cells and when their tips touch, they fuse to form a single conduit. As the name implies, this latter mechanism depends on actin. Several molecules are also implicated in TNT formation, including M-Sec, myosin-Va, myosin-X, synaptophysin, Rho GTPases (cdc42, Rac1), RASSF1A, LST1, and Rab8/Rab11a [25, 32–39].

FIGURE 1: Morphogen transport and the drunken sailor analogy. (a) The transport of morphogens from a source establishes a gradient in the target field. (b–h) Five major morphogen transport models are illustrated using the drunken sailor analogy, in which drunken sailors move by random walks from a ship into a city. In this analogy, morphogen molecules are represented by sailors and cells are represented by buildings. (b) In the case of free diffusion, sailors (green dots) leave the ship (blue oval) and disperse into the city (white square). Inset: sailors take steps of the indicated fixed size, and the direction of each step is random. This “random walk” describes the diffusive behavior of molecules in solution. (c) In the tortuosity-mediated hindered diffusion model, buildings (gray) act as obstacles that sailors must move around, thus increasing the tortuosity of the environment. (d) In the case of diffusion that is hindered by tortuosity and transient binding, the sailors stop in pubs (negative diffusion regulators, yellow) located at the periphery of buildings. Note that, in contrast to effects from tortuosity alone, sailors congregate at the periphery of buildings, and there are relatively few freely moving sailors. (e, f) The shuttling model does not require a localized source of sailors. Instead, sailors are initially present mostly in pubs (negative diffusion regulators, yellow) and uniformly distributed in the city (e). Police officers (positive diffusion regulators, red) disperse from a source on the right side, pick up sailors from pubs, and escort them through the city by preventing further pub visits (f). When police officers disappear (not shown), sailors can reenter the pubs. Over time, this results in the concentration of sailors on the left. (g) In the transcytosis model, the sailors travel through the buildings. (h) During directed transport-mediated by cytonemes, the sailors travel through subway tunnels (orange), which deposit the sailors in buildings (reproduced from Muller et al. 2013) with no alterations under the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/) [1].
The transparent tissue environment of the corneal stroma, with its unique arrangement of collagenous lamellae and absence of pigmentation, likely enabled the first visualization of these elusive cellular structures in a mammalian tissue. Unlike other tissues such as the skin, where resident tissue macrophages and dendritic cells are abundant (approximately 1000 cells/mm²) [41], the density of immune cells in the cornea is comparatively low (100-150 cells/mm²) [42]. Thus, intercellular communication between widely spaced cells in the cornea may be facilitated by the presence of long cellular extensions. In a follow-up study, membrane nanotubes were also identified in the mouse dura mater, which is another dense connective tissue that shares similar structural features with the cornea [43]. Using time-lapse confocal microscopy, nanotube formation in the mouse cornea was dynamically visualized in corneal explants from macrophage GFP reporter mice, with evidence supporting de novo formation, with an average speed of 15 μm/minute.

While the first two reports of TNTs in the mammalian cornea were novel, insights into their proposed function or role in disease were not provided. In a study exploring the potential for treating corneal pathology associated with the lysosomal storage disease, cystinosis, Rocca and colleagues performed a hematopoietic progenitor stem cell transfer from healthy wild-type donor mice into cystinosin gene-deficient animals (ctsns/-/-) [44]. In addition to improving the clinical outcome of ocular pathology, such as corneal thinning and elevated IOP, transfer of transplanted cystinosin lysosomes from healthy donor cells into diseased, recipient cells was observed in corneal macrophages. Macrophage-mediated transfer of healthy cystinosin lysosomes to diseased fibroblasts via TNTs was also demonstrated in vitro [45]. These studies provide compelling evidence that damaged intracellular organelles can be "rescued" by transplantation of healthy donor cells, with TNTs serving as conduits for delivery of the healthy cargo.

2.2. TNTs in the Trabecular Meshwork. The trabecular meshwork (TM) is a small, circumferential, sieve-like tissue located in the anterior segment of the eye. The TM regulates aqueous humor outflow from the anterior chamber and thus establishes intraocular pressure (IOP) [46]. When outflow is disrupted, due to blockages in the TM outflow channels, IOP begins to increase. Elevated IOP is a primary risk factor for glaucoma, a leading cause of blindness worldwide [47]. TM cells sense changes in IOP and communicate signals to
remodel the extracellular matrix to allow greater aqueous fluid flow and alleviate pressure. However, signaling in this aqueous environment is challenging because signals secreted from the cell are immediately diluted in aqueous humor fluid, which can drain into Schlemm’s canal before reaching their target cell. Furthermore, cells in the putative stem cell region of the tissue, posterior to Schwalbe’s line, are not bathed in aqueous humor [48]. Yet, we know that these cells must receive signals because they are induced to migrate into the TM in response to burns placed by laser trabeculoplasty, a common treatment to relieve elevated IOP in glaucoma patients [49]. It is currently unclear how signals released at laser sites can be transported long distances (>100 μm) at high enough concentrations to elicit their effects at the insert region. This suggests additional mechanisms must be employed by TM cells to communicate signals in an aqueous environment.

TNTs formed by cultured TM cells were first described by Keller et al., in 2017 (Figure 4) [50]. In this study, live cell imaging showed the transfer of DiO fluorescently labeled vesicles and mitochondria from one TM cell to another. Over the course of 40 minutes, four vesicles were transferred. Using various manipulations of the actin cytoskeleton, a Rho kinase inhibitor, Y27632, increased the number of vesicles transferred, while inhibition of the Arp2/3 complex with CK-666 reduced vesicle transfer [50]. When glaucoma TM cells were compared to normal TM cells, TNTs were less abundant, but they were longer [51]. Also, the actin cytoskeleton was less dynamic in GTM cells and it appeared that transfer may be bidirectional since both DiO- and DiD-labeled vesicles were present in the same TNT. A greater number of GTM cells contained vesicles of the opposite color compared to normal TM cells, suggesting that a more stabilized actin cytoskeleton could lead to prolonged TNT connections, which, combined with possible bidirectional vesicle transfer, would account for the increased transfer over time. Together, these data provided the first evidence that normal and glaucomatous TM cells utilize TNTs to communicate with each other.

2.3. TNTs in the Retina. The retinal pigment epithelium (RPE) is a monolayer of pigmented cells that provides metabolic support to the photoreceptors in the retina. TNTs have been detected in cultured RPE cells [52]. In these cells, TNTs transferred mitochondria, endosomes, and Ca2+. Transfer of Ca2+ indicates that the TNTs were electrically coupled, which was confirmed by the localization of connexin 43+ gap junctions at the tips of TNTs connecting RPE cells [52]. However, gap junctions cannot transfer larger molecules so another mechanism must exist for organelle transfer. As well as RPE cell communication, TNTs may also play a role in angiogenesis in the retina. A recent study showed that vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1α (HIF-1α) signals can be transferred between malignant ovarian cancer cells and human vascular endothelial cells (HUVEC) [53]. The authors speculated that TNTs could stimulate angiogenesis by propagating these potent angiogenic factors. If similar studies showed that VEGF and HIF-1α were transported by TNTs in retinal cells, a new target for anti-VEGF treatments for diabetic retinopathy, retinopathy of prematurity, and/or wet age-related macular degeneration may be revealed.

Pericytes are mesenchymal-derived cells that encircle endothelial cells of capillaries in the microvasculature. Together with astrocytes and neurons, they form a neurovascular unit that functions to maintain the blood-brain and blood-retina barrier [54]. Retinal pericytes are lost in diabetic retinopathy patients, making retinal capillaries vulnerable to proliferation signals and formation of leaky neovessels which can lead to blindness [55]. In the brain, pericytes form TNTs, which appear to function in probing the environment for...
other cells as well as communicating signals during brain development and during pathological neovascularization [56]. The role of pericyte-derived TNTs in the retina is an unexplored target to prevent abnormal angiogenesis, which underpins the pathogenesis of several blinding diseases affecting the retina.

2.4. Cytonemes in the Drosophila Eye. Like TNTs, cytonemes are specialized filopodia with an actin core (Figure 2). However, instead of forming a tube through which cargo is carried, signals travel along the surface of the cytoneme [7]. Cytonemes were first described by Ramirez-Weber and Kornberg in 1999, who studied decapentaplegic signaling in the Drosophila wing imaginal disc [6]. Later studies investigated epidermal growth factor (EGF) signaling in the Drosophila eye disc and found that epithelial cytonemes, which express the EGF receptor, orient themselves toward the morphogenetic furrow, where the Spi/EGF-producing cells are
located [8]. Thus, cytonemes extend long distances (up to 20 cell diameters) to link EGF producing and receiving cells, which provides specificity in signaling over long distances in tissues [57]. To date, there are no descriptions of cytonemes in the vertebrate eye. Recent reviews describe the similarities and differences between cytonemes and TNTs in more detail [58, 59].

3. Mitochondrial Intercellular Transfer via TNTs and Implications for Eye Diseases

Mitochondrial dysfunction in ocular disease is relatively common, especially in genetic disorders that disrupt their structure or function [60]. Mutations in OPA1 and MFN2 genes cause autosomal dominant optic atrophy (DOA); mutations in WFS1 and CISD2 can cause Wolfram syndrome, while Leber’s hereditary optic neuropathy (LHON) is associated with mutations in mitochondrial ND1, ND4, and ND6 genes [61, 62]. However, many other eye diseases have been linked to mitochondrial dysfunction occurring secondary to other conditions including glaucoma and other optic neuropathies, age-related macular degeneration, diabetic retinopathy, and retinitis pigmentosa [63–71].

Intercellular transfer of mitochondria can occur via TNTs, and it appears to be a common occurrence in cell cultures and possibly in vivo [72, 73]. Mitochondria are ATP generators, and they are essential for cell survival. The transfer of mitochondria between cells was first observed in coculture experiments where healthy mitochondria from human mesenchymal stem cells were transferred via cytoplasmic projections to A549 cells, which have defective or depleted mtDNA [74]. Several recent studies suggested that intercellular transfer of mitochondria is linked to cell survival [16, 17, 75–77]. For instance, Liu et al. [16] showed that mesenchymal stem cell–derived mitochondria rescued oxidatively stressed human umbilical vein endothelial cells (HUVECs) from apoptosis. Other groups have suggested that TNT-mediated transfer could induce differentiation of mesenchymal stem cells into renal tubule cells [27], while mitochondrial transfer in cocultures of endothelial cells and cancer cells conveyed chemoresistance to the cancer cells receiving the mitochondria [78]. Transcellular mitochondrial exchange is not limited to cells in culture with new evidence showing that this process can also occur in vivo where healthy mitochondria were transferred from astrocytes to neurons in the mouse brain [76]. This transfer was CD38-dependent and led to a neuroprotective effect after stroke. While these in vitro and in vivo studies show mitochondrial transfer between heterotypic cell types, other groups describe mitochondrial transfer between homotypic cell types [20, 50, 79]. For instance, Wang and Gerdes demonstrated that mitochondria transferred from untreated, healthy PC12 to UV-stressed PC12 cells reversed the early stages of apoptosis [20]. Little is known about the molecules that are involved in mitochondrial trafficking, but Miro1 appears to be involved [80].

A role for mitochondrial transfer in ocular cells is emerging. In the cornea, mitochondria were transferred via TNTs in cocultures of corneal epithelial cells and mesenchymal stem cells [81]. When MSCs were applied to the corneas of rabbits with alkali burns, mitochondria were transferred to the host corneas. However, it could not be determined whether this transfer was via TNTs or whether it was due to release of mitochondria into the extracellular space for uptake by neighboring cells. In retinal ARPE-19 cells, mitochondria and endocytic organelles were found within the TNT connections [52]. With this discovery, the authors suggested that mitochondria may be transferred between themselves or hypothetically between RPE cells and photoreceptors [52]. While RPE cell culture experiments show TNTs, TNTs in retina tissue in vivo have not yet been reported. This is likely due to their fragility upon fixation and lack of a good biomarker. However, one study hints at their existence. Transcellular mitochondrial exchange between neurons and glia in the optic nerve head (ONH) was recently described [82]. In this study, serial block-face scanning electron microscopy demonstrated that mitochondria shed from ONH-resident neurons were engulfed and degraded by lysosomes in neighboring astrocytes. It is possible that direct connections via TNTs were involved in this mitochondrial transfer, but the thin tubules may have been destroyed during the harsh fixation treatments used in the preparation procedures used for electron microscopy. While speculative, studies such as these are highlighting the importance of intercellular transfer of mitochondria and TNTs as a potential mechanism of transfer.

4. Molecular Regulation of TNTs in the Eye

Several molecules play a role in TNT biogenesis, and some of these have roles in various physiological processes in the eye. For instance, Rab8a/Rab11a and myosin-Va, which are associated with TNTs [2, 37], have been found to be involved in normal photoreceptor signaling in the retina [83, 84]. In Xenopus and zebrafish photoreceptors, Rab8a/Rab11a are involved in transporting rhodopsin from the Golgi to the dominant inner segment membranes, the first step before intracellular transport to the outer segment. However, the role of Rab8a/Rab11a in the mammalian eye appears more complex since they are dispensable for the transport of rhodopsin to the mouse outer segment [84]. Further studies are needed to resolve the contribution of these proteins to TNT biogenesis and normal homeostatic processes in the eye. However, one TNT regulator, myosin-X (Myo10), appears to play a major role in TNT-mediated processes in the eye, which we will now describe in more detail.

4.1. Myo10 Background. Several groups have described a role of Myo10 in filopodia and TNT formation [85–87]. Myo10 belongs to a group of four unconventional myosins—Myo7a, Myo7b, Myo10, and Myo15a—which, unlike conventional myosins, do not form filaments and are not involved in muscle contraction [88]. Myo10 was first described by Berg et al. [89] and is localized to areas of dynamic actin reorganization. It is composed of an actin-binding head domain, a neck domain, and a tail domain, which is involved in binding of cargo and dimerization [90]. The head domain of Myo10 binds to F-actin and acts as a molecular motor, hydrolyzing ATP to transport itself along the actin filaments. The head domain is essential for this transport since "headless"
recombinant constructs do not travel along filopodia [91]. Some cell types such as neurons express an endogenous “headless” Myo10, which negatively regulates full-length Myo10 [92, 93]. The neck domain of Myo10, which contains IQ motifs, may regulate the motor activity of the head domain or increase flexibility of the molecule as it walks hand-over-hand along actin filaments [94]. The tail domain offers diversity from the other unconventional myosins and is composed of a coiled-coil region, three PEST domains, three PH domains, a myosin tail homology 4 (MyTH4), and a band 4.1, ezrin, radixin, moesin (FERM) domain [90]. The coiled-coil domain is important for dimer formation. The antiparallel coiled-coil structure of Myo10 dimers is optimized to move on actin filaments rather than single actin filaments [95]. The MyTH4 and FERM domains in the tail domain also bind several different molecules including microtubulin, β-integrin, and the VE-cadherin complex [96–98].

4.2. Myo10 Role in Filopodia and TNT Formation. Overexpression of Myo10 in a variety of cell types increases the number of filopodia emanating from the cell surface, while Myo10 knockdown reduces filopodia number [85, 86, 91, 99, 100]. Overexpression of Myo10, but not VASP or fascin, also induced TNT formation [87]. Other studies show that Myo10 appears to play multiple roles in filopodia/TNT formation including at the initiation and elongation phases [86, 101]. Shorter filopodia predominated when the C-terminal FERM domain was eliminated [86]. Live cell imaging using GFP-tagged Myo10 constructs shows Myo10 in bright puncta at the filopodia tips and along the length of the cellular protrusion [90, 91]. Fainter Myo10 clusters were also apparent along the filopodial shaft. The bright puncta travel at around 80 nm/second, while the faint Myo10 moves even faster at around 600 nm/sec [90]. Myo10 also undergoes retrograde movement but at much slower speeds of 15 nm/sec, a rate that is similar to the retrograde flow of actin [102]. There is some controversy of whether Myo10 moves faster on actin filaments or bundles [95, 103, 104]. Differences may be due to the origin of actin bundles used in each study, i.e., fascin-induced actin bundles versus nascent filopodia, which presumably contain additional actin-binding proteins. Together, these studies demonstrate that Myo10 plays a critical role in TNT biogenesis, elongation, and cargo transport.

4.3. Eye Phenotypes Caused by Myo10 Knockdown and Knockout. Myo10 is expressed in the retina and the TM [105–107]. Recent RNAi knockdown studies and knockout mouse models have revealed functional roles for Myo10 in the eye. In an anterior eye study, RNAi silencing lentivirus was generated to selectively knock down Myo10 in TM tissue and cells [107]. First, Myo10 silencing lentivirus was applied to an ex vivo organ culture perfusion model to examine the effects on outflow and IOP regulation [107]. Outflow rates were significantly reduced suggesting that Myo10-mediated filopodia/TNTs play a role in IOP regulation. In Myo10-silenced TM cell cultures, matrix metalloproteinase activity was reduced, consistent with a reduction in focal remodeling of the extracellular matrix components of the outflow resistance. Of note, Myo10 protein distribution in glaucomatous TM tissue was disrupted compared to age-matched normal tissue [51].

Two Myo10 knockout mouse models were recently described, and both have posterior chamber ocular phenotypes (Figure 5) [105, 106]. The first knockout model ablated both full-length and headless forms of Myo10 [105]. Between embryonic days E12.5 and E17.5, approximately 60% of Myo10 knockout mice exhibited exencephaly, a lethal neural tube closure defect. However, 40% of homozygotes survived to adulthood. Of these survivors, all exhibited a white belly spot and persistent fetal vasculature (PVF) in the eye (Figures 5(a) and 5(b)). Other less penetrant phenotypes included kinked tails and soft tissue syndactyly of the digits. The bilateral persistent hyaloid vasculature in the posterior eye was phenotypically similar to the human disease PVF. In normal mice, the hyaloid vasculature develops around E12.5 and is resorbed soon after birth (2-3 weeks). In Myo10 knockout mice, hyaloid regression was dysfunctional and a thin strand, which emanated from the optic disc, extended through the vitreous, and connected to the posterior lens, persisted. Retinal angiogenesis was also delayed in Myo10/- mice. Analysis of the retina using the endothelial biomarker, PECAM-1, showed that the retinal vascular network was less dense, and the endothelial cells had 50% less filopodia (Figure 5) [105]. Other eye defects such as embryonic microphthalmia, anophthalmia, an optic fissure closure defect, cloudy cornea, and lens spots were noted, but these were sporadic [105].

A second Myo10 knockout mouse was developed, which selectively knocked out the full-length Myo10 molecule, the actin-binding form, but “headless” Myo10 expression was unaffected [106]. Similar to the complete Myo10 knockout, persistent hyaloid vasculature, white belly spots, and syndactyly were common, but there was a reduced rate of exencephaly (24%) (Figure 5(c)). Surprisingly, there was no vascularization defects noted despite Myo10 being the most strongly expressed unconventional myosin in retinal vascular endothelial cells. This selective knockout shows that full-length Myo10 is important for hyaloid regression, but not retinal vascularization. Together, these mouse models indicate that Myo10 is required for normal embryonic development and is important for filopodia formation in vivo.

5. Role of TNTs in Diseases Relevant to Vision Research

In addition to their potential role in ocular disease, TNTs are involved in many other pathological disease processes. Several recent review papers provide discussion of TNTs in health and disease in greater detail [39, 108–111]. Here, we review the role of TNTs in several pathological processes of particular interest to vision scientists.

5.1. Inflammatory Responses. Acute and chronic inflammation underpins a wide variety of ocular diseases, which can have both local and systemic origins. Inflammation is a known stimulator of TNT formation in immune cells [40, 112], but the precise functional significance of this is unclear. Theoretically,
Figure 5: Phenotype of two Myo10 knockout mouse models. tm1d completely ablated all Myo10 forms, whereas tm2 selectively knocked out the full-length, actin-binding Myo10, but "headless" Myo10 expression was unaffected. (a) Fluorescence image of flat mounted retinas showing retinal vasculature at P5. Dissected retinas were stained with a PECAM-1 antibody (green) and counterstained with phalloidin (red). The retinal vasculature extended to similar positions in the control and Myo10tm1d/tm1d eyes. The image represents a stitch of micrographs taken at 20x and is best visualized if the images are enlarged on a digital display. (b) High-resolution images of the angiogenic expansion front from the P5 retinas in (a) showing filopodia radiating from endothelial tips cells. Loss of Myo10 results in a decreased number of filopodia and leads to a less dense vascular network. Images were captured as Z-stacks at 60x and displayed as maximum projections with the PECAM-1 channel displayed in inverted grayscale to highlight endothelial filopodia. (c) High-resolution MRI (magnetic resonance imaging) of enucleated and fixed eyes from adult wild-type (WT) and Myo10tm2/tm2 mice, where representative of 6 eye scans for each genotype reveals persistence of the hyaloid vasculature in mutant mice. The hyaloid artery emerges from the optic disc and extends toward the lens, as schematically illustrated on the right. Scale bars: 1 mm (reproduced from (a, b) Heimsath et al. 2017 and (c) Bachg et al. 2019 under the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/)) [105, 106].
TNT could be exploited in vivo to deliver immunomodulating proteins that could inhibit or promote inflammation, depending on the therapeutic need. In a study on the feasibility of synthetic nanotubes as a drug delivery system, peptide nanotubes were designed to deliver Caspase-3 siRNA as a means to inhibit keratocyte apoptosis in the injured mouse corneal stroma [113]. While this study was based on exogenous nanotube delivery to the wounded cornea, it does provide evidence that nanotube-mediated transfer of therapeutic siRNA could occur in vivo. In vitro evidence suggests that when fibroblasts are cocultured with TGF-β1-stimulated dendritic cells, membrane nanotube formation increases. Furthermore, tenascin-C, a prorregenerative extracellular matrix molecule, was localized to the TNTs [114], suggesting that exposure to certain growth factors can promote the formation of TNTs between fibroblasts and possibly contribute to tissue remodeling. Whether the delivery of drugs or therapies aimed at suppressing ocular inflammation could also apply to biological TNTs, either through donor cell transfer or by upregulating endogenous TNT formation in vivo, is a largely unexplored and exciting future area of research.

5.2. Cancer. Several studies have investigated the role of TNTs in cancer (reviewed in [111]). Of particular interest to vision researchers is the role of the tumor suppressor gene, RASSF1A, in uveal melanomas [115]. RASSF1A binds cytoskeletal proteins such as actin and microtubules, playing an important role in TNT formation, cell cycle regulation, and apoptosis to maintain cellular homeostasis [35, 111]. Loss of RASSF1A gene expression is observed in certain cancers, including uveal melanomas in the eye [115, 116]. In malignant mesothelial cell lines, downregulation of RASSF1A increased the number of TNT connections, while overexpression decreased the TNT number and length [35]. Thus, increased TNT-mediated communication concomitant with downregulation of RASSF1A appears linked to cancer progression. RASSF1A is downregulated in uveal melanoma tumors as well as in uveal melanoma cell lines [115]. Therefore, it seems plausible that TNT communication is involved in uveal melanomas.

5.3. Stem Cells. Therapeutic stem cell transplantation is a hot area of vision research. Recent evidence suggests that stem cells may not necessarily integrate as functioning cells but rather exert a local trophic influence to regenerate host cells [117]. In vitro studies have reported the transfer of mitochondria and other cellular organelles between heterotypic cell types such as mesenchymal stem cells and endothelial cells [16, 17, 45, 75, 81, 118–120]. Many of these studies also describe that formation of TNT connections “rescues” dying cells. In the cornea, hematopoietic stem progenitor cells (HSPCs) were transplanted into cystinosin-null mice and these were found to home to the cornea to restore normal corneal structure and function [44]. Interestingly, some of these HSPCs differentiated into macrophages, which formed TNTs that appeared to transport cystinosin-containing lysosomes into adjacent diseased cells. Thus, control of TNTs may provide a novel mechanism to transport normal proteins to diseased cells in lysosomal storage diseases [121].

Transplantation of stem cells has also been suggested as a therapeutic option for glaucoma [48, 122]. Stem cells may provide a source of factors that promote survival of resident cells or modulate the intraocular microenvironment. Mesenchymal stem cell (MSC) transplantation has shown to be neuroprotective for RGCs [122], and MSCs offer an attractive therapeutic option for repopulating the cells of the TM of POAG patients, which have a marked reduction in the TM cell number [123]. Several groups have shown that introduction of MSCs [124], or induced pluripotent stem cells (iPSCs) [125–127], may restore TM IOP regulation function. In both anterior and posterior glaucoma stem cell therapies, it is conceivable that TNTs formed between stem cells and resident cells could promote survival of the remaining endogenous host cells. Further studies are required to explore these possibilities.

6. Future Perspectives: Potential Applications of TNTs in Ocular Therapies

A growing area of ocular research concerns the delivery of drugs and gene therapies [128–131]. Many papers have described the use of nanoparticles as drug delivery systems, which offer attractive advantages over conventional methods including targeted delivery, increased drug bioavailability with lower doses, sustained release, and reduced side effects [132]. Nanoparticles can be used to deliver a variety of payloads such as ocular gene therapies, contrasts agents for bioimaging, nanodrugs, and/or antimicrobial agents [133]. He et al. reported that quantum dots made from CdSe/ZnS (15-20 nm diameter) were rapidly internalized by cardiac myocytes and were transported bidirectionally via TNTs [24]. Subsequently, other researchers showed that nanoparticles made from porous silicon (3.2 μm diameter) were directly transferred between cells via TNTs [134]. These studies in other tissues of the body suggest that TNTs may be used to deliver nanoparticles to specific tissues in the eye.

Viruses can spread via TNTs [7], which could be exploited to deliver viral-mediated gene therapies in the eye. Recently, the first gene therapy, Luxturna, received FDA approval. This modified, inactive AAV2 virus is delivered by subretinal injection to replace defective RPE65 in children with Leber’s congenital amaurosis [135]. Since RPE cells in vitro communicate via TNTs [52], it is conceivable that TNTs could be utilized to provide more effective delivery of virus-mediated gene therapies to targeted photoreceptor cells in the retina. However, multiple challenges remain and more research is needed to reveal how TNTs can be manipulated to form de novo to ensure efficient transport of the nanoparticles or viruses in vivo.

7. Final Thoughts

The current knowledge of TNTs in specific ocular tissues is summarized in Figure 6. While the discovery of TNTs has challenged existing dogma and opened up new avenues for research into how cells communicate, there are still many outstanding questions that need to be addressed. Studies on signals, mechanisms, and/or microenvironments that initiate
their creation, as well as determining the molecules involved in their elongation, stability, and collapse, will likely yield novel ways that we can control TNTs. Improvements in high-resolution, intravital imaging techniques and development of specific fluorescent reporter mice will enable further investigation into the physiology of TNT formation in ocular tissues in vivo. Targeted inhibition of key proteins, or RNA silencing of genes involved in TNT formation, in specific tissues and cell populations will also lead to further understanding of the function of TNTs during ocular homeostasis and during disease. This should open new avenues of research to design novel therapies for the treatment of a wide range of eye diseases.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

This work was supported by NIH/NEI (R01 EY019643 (KEK), EY010572 (P30 Casey Eye Institute Core facility grant)), an unrestricted grant to the Casey Eye Institute from Research to Prevent Blindness, New York, NY, and National Health and Medical Research Council (NH&MRC) Project Grant (APP1042612 (HRC)).

References

[1] P. Muller, K. W. Rogers, S. R. Yu, M. Brand, and A. F. Schier, “Morphogen transport,” Development, vol. 140, no. 8, pp. 1621–1638, 2013.
[2] A. Rustom, R. Saffrich, I. Markovic, P. Walther, and H. H. Gerdes, “Nanotubular highways for intercellular organelle transport,” Science, vol. 303, no. 5660, pp. 1007–1010, 2004.
[3] D. M. Davis and S. Sowinski, “Membrane nanotubes: dynamic long-distance connections between animal cells,” Nature Reviews Molecular Cell Biology, vol. 9, no. 6, pp. 431–436, 2008.
[4] H. H. Gerdes, A. Rustom, and X. Wang, “Tunneling nanotubes, an emerging intercellular communication route in development,” Mechanisms of Development, vol. 130, no. 6–8, pp. 381–387, 2013.
[5] S. Gurke, J. F. Barroso, and H. H. Gerdes, “The art of cellular communication: tunneling nanotubes bridge the divide,” Histochemistry and Cell Biology, vol. 129, no. 5, pp. 539–550, 2008.
[6] F. A. Ramirez-Weber and T. B. Kornberg, “Cytonemes: cellular processes that project to the principal signaling center in Drosophila imaginal discs,” Cell, vol. 97, no. 5, pp. 599–607, 1999.
[7] N. M. Sherer and W. Mothes, “Cytonemes and tunneling nanotubes in cell-cell communication and viral pathogenesis,” Trends in Cell Biology, vol. 18, no. 9, pp. 414–420, 2008.
Biology presenting a novel route for HIV-1 transmission, nanotubes physically connect T cells over long distances pre-
2015.
–
neurodegenerative diseases,
 proteins by lysosomes and tunneling nanotubes: implications for neurodegenerative diseases,” The Journal of Cell Biology, vol. 216, no. 9, pp. 2633–2644, 2017.
[11] X. Wang and H. H. Gerdes, “Long-distance electrical coupling via tunneling nanotubes,” Biochimica et Biophysica Acta, vol. 1818, no. 8, pp. 2082–2086, 2012.
[12] B. Önfelt, S. Nedvetzki, R. K. P. Benninger et al., “Structurally distinct membrane nanotubes between human macrophages support long-distance vesicular traffic or surfing of bacteria,” Journal of Immunology, vol. 177, no. 12, pp. 8476–8483, 2006.
[13] B. Önfelt, M. A. Purbho, S. Nedvetzki, S. Sowinski, and D. M. Davis, “Long-distance calls between cells connected by tunneling nanotubes,” Science Signaling, vol. 2005, no. 313, article pe55, 2005.
[14] H. H. Gerdes and R. N. Carvalho, “Intercellular transfer mediated by tunneling nanotubes,” Current Opinion in Cell Biology, vol. 20, no. 4, pp. 470–475, 2008.
[15] K. He, X. Shi, X. Zhang et al., “Long-distance intercellular connectivity between cardiomyocytes and fibroblasts mediated by membrane nanotubes,” Cardiovascular Research, vol. 92, no. 1, pp. 39–47, 2011.
[16] K. Liu, K. Ji, L. Guo et al., “Mesenchymal stem cells rescue injured endothelial cells in an in vitro ischemia-reperfusion model via tunneling nanotube like structure-mediated mitochondrial transfer,” Microvascular Research, vol. 92, pp. 10–18, 2014.
[17] M. N. Islam, S. R. Das, M. T. Emin et al., “Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury,” Nature Medicine, vol. 18, no. 5, pp. 759–765, 2012.
[18] I. Kadiu and H. E. Gendelman, “Macrophage bridging conduit trafficking of HIV-1 through the endoplasmic reticulum and Golgi network,” Journal of Proteome Research, vol. 10, no. 7, pp. 3225–3238, 2011.
[19] L. Marzo, K. Goussot, and C. Zurzolo, “Multifaceted roles of tunneling nanotubes in intercellular communication,” Frontiers in Physiology, vol. 3, p. 72, 2012.
[20] X. Wang and H. H. Gerdes, “Transfer of mitochondria via tunneling nanotubes rescues apoptotic PC12 cells,” Cell Death and Differentiation, vol. 22, no. 7, pp. 1181–1191, 2015.
[21] S. Sowinski, C. Jolly, O. Berninghausen et al., “Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission,” Nature Cell Biology, vol. 10, no. 2, pp. 211–219, 2008.
[22] K. Goussot, E. Schiff, C. Langevin et al., “Prions hijack tunneling nanotubes for intercellular spread,” Nature Cell Biology, vol. 11, no. 3, pp. 328–336, 2009.
[23] G. S. Victoria and C. Zurzolo, “The spread of prion-like proteins by lysosomes and tunneling nanotubes: implications for neurodegenerative diseases,” The Journal of Cell Biology, vol. 216, no. 9, pp. 2633–2644, 2017.
[24] K. He, W. Luo, Y. Zhang et al., “Intercellular transportation of quantum dots mediated by membrane nanotubes,” ACS Nano, vol. 4, no. 6, pp. 3015–3022, 2010.
[25] K. Hase, S. Kimura, H. Takatsu et al., “M-Sec promotes membrane nanotube formation by interacting with Ral and the exocyst complex,” Nature Cell Biology, vol. 11, no. 12, pp. 1427–1432, 2009.
[26] S. C. Watkins and R. D. Salter, “Functional connectivity between immune cells mediated by tunneling nanotubes,” Immunity, vol. 23, no. 3, pp. 309–318, 2005.
[27] E. Y. Plotnikov, T. G. Khrypenkova, S. I. Galkina, G. T. Sukhikh, and D. B. Zorov, “Cytoplasm and organelle transfer between mesenchymal multipotent stromal cells and renal tubular cells in co-culture,” Experimental Cell Research, vol. 316, no. 15, pp. 2447–2455, 2010.
[28] M. Climent, M. Quintavalle, M. Miragoli, J. Chen, G. Condorelli, and L. Elia, “TGFβ triggers miR-143/145 transfer from smooth muscle cells to endothelial cells, thereby modulating vessel stabilization,” Circulation Research, vol. 116, no. 11, pp. 1753–1764, 2015.
[29] X. Wang, N. V. Bukoreshtliev, and H. H. Gerdes, “Developing neurons form transient nanotubes facilitating electrical coupling and calcium signaling with distant astrocytes,” PLoS One, vol. 7, no. 10, article e47429, 2012.
[30] S. Abounit and C. Zurzolo, “Wiring through tunneling nanotubes— from electrical signals to organelle transfer,” Journal of Cell Science, vol. 125, Part 5, pp. 1089–1098, 2012.
[31] M. Drab, D. Stopar, V. Kralj-Iglič, and A. Iglič, “Inception mechanisms of tunneling nanotubes,” Cell, vol. 8, no. 6, p. 626, 2019.
[32] S. Kimura, M. Yamashita, M. Yamakami-Kimura et al., “Distinct roles for the N- and C-terminal regions of M-Sec in plasma membrane deformation during tunneling nanotube formation,” Scientific Reports, vol. 6, no. 1, article 33548, 2016.
[33] S. Kimura, K. Hase, and H. Ohno, “The molecular basis of induction and formation of tunneling nanotubes,” Cell and Tissue Research, vol. 352, no. 1, pp. 67–76, 2013.
[34] S. J. Hanna, K. McCoy-Simandle, V. Miskolci et al., “The role of rho-GTPases and actin polymerization during macrophage tunneling nanotube biogenesis,” Scientific Reports, vol. 7, no. 1, article 8547, 2017.
[35] F. Dubois, B. Jean-Jacques, H. Roberge et al., “A role for RASSF1A in tunneling nanotube formation between cells through GEFH1/Rab11 pathway control,” Cell Communication and Signaling, vol. 16, no. 1, p. 66, 2018.
[36] C. Schiller, K. N. Diakopoulos, I. Rohwedder et al., “LST1 promotes the assembly of a molecular machinery responsible for tunneling nanotube formation,” Journal of Cell Science, vol. 126, Part 3, pp. 767–777, 2013.
[37] S. Zhu, S. Bhat, S. Syan, Y. Kuchitsu, M. Fukuda, and C. Zurzolo, “Rab11a-Rab8α cascade regulates the formation of tunneling nanotubes through vesicle recycling,” Journal of Cell Science, vol. 131, no. 19, 2018.
[38] H. Zhu, C. Xue, X. Xu et al., “Rab8α/Rab11a regulate intercellular communications between neural cells via tunneling nanotubes,” Cell Death & Disease, vol. 7, no. 12, article e2523, 2016.
[39] J. Ariazi, A. Benowitz, V. De Biasi et al., “Tunneling nanotubes and gap junctions—their role in long-range intercellular communication during development, health, and disease.
conditions,” *Frontiers in Molecular Neuroscience*, vol. 10, p. 333, 2017.

[40] H. R. Chinnery, E. Pearlman, and P. G. McMenamin, “Cutting edge: membrane nanotubes in vivo: a feature of MHC class II” cells in the mouse cornea,” *The Journal of Immunology*, vol. 180, no. 9, pp. 5779–5783, 2008.

[41] J. Bauer, F. A. Bahmer, J. Worl, W. Neuhuber, G. Schuler, and M. Fartasch, “A strikingly constant ratio exists between Langhans cells and other epidermal cells in human skin. A stereologic study using the optical dissector method and the confocal laser scanning microscope,” *The Journal of Investigative Dermatology*, vol. 116, no. 2, pp. 313–318, 2001.

[42] Y. Seyed-Razavi, M. J. Lopez, D. Mantopoulos et al., “Kinetics of corneal leukocytes by intravitral multiphoton microscopy,” *The FASEB Journal*, vol. 33, no. 2, pp. 2199–2211, 2019.

[43] Y. Seyed-Razavi, M. J. Hickey, L. Kuffova, P. G. McMenamin, and H. R. Chinnery, “Membrane nanotubes in myeloid cells in the adult mouse cornea represent a novel mode of immune cell interaction,” *Immunology and Cell Biology*, vol. 91, no. 1, pp. 89–95, 2013.

[44] C. J. Rocca, A. Kreymerman, S. N. Ur et al., “Treatment of inherited eye defects by systemic hematopoietic stem cell transplantation,” *Investigative Ophthalmology & Visual Science*, vol. 56, no. 12, pp. 7214–7223, 2015.

[45] S. Naphade, J. Sharma, H. P. Gaide Chevornnay et al., “Brief reports: lysosomal cross-correction by hematopoietic stem cell-derived macrophages via tunneling nanotubes,” *Stem Cells*, vol. 33, no. 1, pp. 301–309, 2015.

[46] J. A. Vranka, M. J. Kelley, T. S. Acott, and K. E. Keller, “Extracellular matrix in the trabecular meshwork: intraocular pressure regulation and dysregulation in glaucoma,” *Experimental Eye Research*, vol. 133, pp. 112–125, 2015.

[47] H. A. Quigley, “Glaucoma,” *The Lancet*, vol. 377, no. 9774, pp. 1367–1377, 2011.

[48] M. J. Kelley, A. Y. Rose, K. E. Keller, H. Hessle, J. R. Samples, and T. S. Acott, “Stem cells in the trabecular meshwork: present and future promises,” *Experimental Eye Research*, vol. 88, no. 4, pp. 747–751, 2009.

[49] T. S. Acott, J. R. Samples, J. M. Bradley, D. R. Bacon, S. S. Bylisma, and E. M. Van Buskirk, “Trabecular repopulation by anterior trabecular meshwork cells after laser trabeculoplasty,” *Journal of American Ophthalmology*, vol. 107, no. 1, pp. 1–6, 1989.

[50] K. E. Keller, J. M. Bradley, Y. Y. Sun, Y. F. Yang, and T. S. Acott, “Tunneling nanotubes are novel cellular structures that communicate signals between trabecular meshwork cells,” *Investigative Ophthalmology & Visual Science*, vol. 58, no. 12, pp. 5298–5307, 2017.

[51] Y. Y. Sun, J. M. Bradley, and K. E. Keller, “Phenotypic and functional alterations in tunneling nanotubes formed by glaucomatous trabecular meshwork cells,” *Investigative Ophthalmology & Visual Science*, vol. 60, no. 14, pp. 4583–4595, 2019.

[52] D. Wittig, X. Wang, C. Walter, H. H. Gerdes, R. H. Funk, and C. Roehlecke, “Multi-level communication of human retinal pigment epithelial cells via tunneling nanotubes,” *PLoS One*, vol. 7, no. 3, article e33195, 2012.

[53] E. Lou, E. Zhai, A. Sarkari et al., “Cellular and molecular networking within the ecosystem of cancer cell communication via tunneling nanotubes,” *Frontiers in Cell and Development Biology*, vol. 6, p. 95, 2018.

[54] E. A. Winkler, R. D. Bell, and B. V. Zlokovic, “Central nervous system pericytes in health and disease,” *Nature Neuroscience*, vol. 14, no. 11, pp. 1398–1405, 2011.

[55] H. P. Hammes, Y. Feng, F. Pfister, and M. Brownlee, “Diabetic retinopathy: targeting vasoregression,” *Diabetes*, vol. 60, no. 1, pp. 9–16, 2011.

[56] M. Errede, D. Mangieri, G. Longo et al., “Tunneling nanotubes evoke pericyte/endothelial communication during normal and tumoral angiogenesis,” *Fluids Barriers CNS*, vol. 15, no. 1, p. 28, 2018.

[57] T. B. Kornberg and S. Roy, “Cytorners as specialized signaling filopodia,” *Development*, vol. 141, no. 4, pp. 729–734, 2014.

[58] M. Busczak, M. Inaba, and Y. M. Yamashita, “Signaling by cellular protrusions: keeping the conversation private,” *Trends in Cell Biology*, vol. 26, no. 7, pp. 526–534, 2016.

[59] Y. M. Yamashita, M. Inaba, and M. Busczak, “Specialized intercellular communications via cytonemes and nanotubes,” *Annual Review of Cell and Developmental Biology*, vol. 34, no. 1, pp. 59–84, 2018.

[60] P. Yu-Wai-Man and N. J. Newman, “Inherited eye-related disorders due to mitochondrial dysfunction,” *Human Molecular Genetics*, vol. 26, no. R1, pp. R12–R20, 2017.

[61] A. H. Manickam, M. J. Michael, and S. Ramasamy, “Mitochondrial genetics and therapeutic overview of Leber’s hereditary optic neuropathy,” *Indian Journal of Ophthalmology*, vol. 65, no. 11, pp. 1087–1092, 2017.

[62] C. Zanna, A. Ghelli, A. M. Porcelli et al., “OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion,” *Brain*, vol. 131, Part 2, pp. 352–367, 2008.

[63] Y. A. Ito and A. Di Polo, “Mitochondrial dynamics, transport, and quality control: a bottleneck for retinal ganglion cell viability in optic neuropathies,” *Mitochondrion*, vol. 36, pp. 186–192, 2017.

[64] N. A. Vallabh, V. Romano, and C. E. Willoughby, “Mitochondrial dysfunction and oxidative stress in corneal disease,” *Mitochondrion*, vol. 36, pp. 103–113, 2017.

[65] E. Lefevere, A. K. Toft-Kehler, R. Vohra, M. Kolko, L. Moons, and I. Van Hove, “Mitochondrial dysfunction and diabetic retinopathy,” *Journal of Glaucoma*, vol. 18, no. 2, pp. 93–100, 2009.

[66] E. E. Brown, A. S. Lewin, and J. D. Ash, “Mitochondrial dysfunction underlying outer retinal diseases,” *Mitochondrion*, vol. 36, pp. 66–76, 2017.

[67] K. Kamel, M. Farrell, and C. O’Brien, “Mitochondrial dysfunction in ocular disease: focus on glaucoma,” *Mitochondrion*, vol. 35, pp. 44–53, 2017.

[68] T. Bek, “Mitochondrial dysfunction and diabetic retinopathy,” *Mitochondrion*, vol. 36, pp. 4–6, 2017.

[69] G. Y. Kong, N. J. Van Bergen, I. A. Trounce, and J. G. Crowston, “Mitochondrial dysfunction and glaucoma,” *Journal of Glaucoma*, vol. 18, no. 2, pp. 93–100, 2009.

[70] E. E. Brown, A. S. Lewin, and J. D. Ash, “Mitochondria: potential targets for protection in age-related macular degeneration,” *Advances in Experimental Medicine and Biology*, vol. 1074, pp. 11–17, 2018.

[71] K Mohanty, R. Dada, and T. Dada, “Neurodegenerative eye disorders: role of mitochondrial dynamics and genomics,” *Asia-Pacific Journal of Ophthalmology*, vol. 5, no. 4, pp. 293–299, 2016.

[72] M. Barot, M. R. Gokulgandhi, and A. K. Mitra, “Mitochondrial dysfunction in retinal diseases,” *Current Eye Research*, vol. 36, no. 12, pp. 1069–1077, 2011.
[72] D. Torralba, F. Baixauli, and F. Sanchez-Madrid, “Mitochondria know no boundaries: mechanisms and functions of intercellular mitochondrial transfer,” *Frontiers in Cell and Development Biology*, vol. 4, p. 107, 2016.

[73] M. V. Berridge, M. J. McConnell, C. Grasso, M. Bajzikova, J. Kovarova, and J. Neuzil, “Horizontal transfer of mitochondria between mammalian cells: beyond co-culture approaches,” *Current Opinion in Genetics & Development*, vol. 38, pp. 75–82, 2016.

[74] J. L. Spees, S. D. Olson, M. J. Whitney, and D. J. Prockop, “Mitochondrial transfer between cells can rescue aerobic respiration,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 5, pp. 1283–1288, 2006.

[75] T. Ahmad, S. Mukherjee, B. Pattnaik et al., “Miro1 regulates intercellular mitochondrial transport & enhances mesenchymal stem cell rescue efficacy,” *The EMBO Journal*, vol. 33, no. 9, pp. 994–1010, 2014.

[76] K. Hayakawa, E. Esposito, X. Wang et al., “Transfer of mitochondria from astrocytes to neurons after stroke,” *Nature*, vol. 535, no. 7613, pp. 551–555, 2016.

[77] R. Moschoi, V. Imbert, M. Nebout et al., “Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy,” *Blood*, vol. 128, no. 2, pp. 253–264, 2016.

[78] J. Pasquier, B. S. Guerrouahen, H. Al Thawadi et al., “Differential transfer of mitochondria from endothelial to cancer cells through tunneling nanotubes modulates chemoresistance,” *Journal of Translational Medicine*, vol. 11, no. 1, p. 94, 2013.

[79] A. S. Tan, J. W. Baty, L. F. Dong et al., “Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA,” *Cell Metabolism*, vol. 21, no. 1, pp. 81–94, 2015.

[80] G. Las and O. S. Shirihai, “Miro1: new wheels for transferring mitochrondria,” *The EMBO Journal*, vol. 33, no. 9, pp. 939–941, 2014.

[81] D. Jiang, F. Gao, Y. Zhang et al., “Mitochondrial transfer of mesenchymal stem cells effectively protects corneal epithelial cells from mitochondrial damage,” *Cell Death & Disease*, vol. 7, no. 11, article e2467, 2016.

[82] C. H. Davis, K. Y. Kim, A. E. Bushong et al., “Transcellular degradation of axonal mitochondria,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 111, no. 26, pp. 9633–9638, 2014.

[83] R. T. Libby, C. Lillo, J. Kitamoto, D. S. Williams, and K. P. Stein, “Myosin Va is required for normal photoreceptor synaptic activity,” *Journal of Cell Science*, vol. 117, no. 19, pp. 4509–4515, 2004.

[84] G. Ying, C. D. Gerstner, J. M. Frederick, S. L. Boye, W. H. Hauswirth, and W. Baehr, “Small GTPases Rab8a and Rab11a are dispensable for rhodopsin transport in mouse photoreceptors,” *PLoS One*, vol. 11, no. 8, article e0161236, 2016.

[85] A. B. Bohil, B. W. Robertson, and R. E. Cheney, “Myosin X is a molecular motor that functions in filopodia formation,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 33, pp. 12411–12416, 2006.

[86] T. M. Watanabe, H. Tokuo, K. Gonda, H. Higuchi, and M. Ikebe, “Myosin-X induces filopodia by multiple elongation mechanism,” *The Journal of Biological Chemistry*, vol. 285, no. 25, pp. 19605–19614, 2010.

[87] K. Gousseit, L. Marzo, P. H. Commerre, and C. Zuzolo, “Myo10 is a key regulator of TNT formation in neuronal cells,” *Journal of Cell Science*, vol. 126, Part 19, pp. 4424–4435, 2013.

[88] R. E. Cheney and M. S. Moosiker, “Unconventional myosins,” *Current Opinion in Cell Biology*, vol. 4, no. 1, pp. 27–35, 1992.

[89] J. S. Berg, B. H. Derfler, C. M. Pennisi, D. P. Corey, and R. E. Cheney, “Myosin-X, a novel myosin with pleckstrin homology domains, associates with regions of dynamic actin,” *Journal of Cell Science*, vol. 113, Part 19, pp. 3439–3451, 2000.

[90] M. L. Kerber and R. E. Cheney, “Myosin-X: a MyTH-FERM myosin at the tips of filopodia,” *Journal of Cell Science*, vol. 124, Part 22, pp. 3733–3741, 2011.

[91] J. S. Berg and R. E. Cheney, “Myosin-X is an unconventional myosin that undergoes intrafilopodial motility,” *Nature Cell Biology*, vol. 4, no. 3, pp. 246–250, 2002.

[92] A. N. Raines, S. Nagdas, M. L. Kerber, and R. E. Cheney, “Headless Myo10 is a negative regulator of full-length Myo10 and inhibits axon outgrowth in cortical neurons,” *The Journal of Biological Chemistry*, vol. 287, no. 30, pp. 24873–24883, 2012.

[93] A. D. Sousa, J. S. Berg, R. B. Meeker, and R. E. Cheney, “Myo10 in brain: developmental regulation, identification of a headless isoform and dynamics in neurons,” *Journal of Cell Science*, vol. 119, Part 1, pp. 184–194, 2006.

[94] Y. Sun, O. Sato, F. Ruhnow, M. E. Arsenault, M. Ikebe, and Y. E. Goldman, “Single-molecule stepping and structural dynamics of myosin X,” *Nature Structural & Molecular Biology*, vol. 17, no. 4, pp. 485–491, 2010.

[95] V. Ropars, Z. Yang, T. Isabel et al., “The myosin X motor is optimized for movement on actin bundles,” *Nature Communications*, vol. 7, no. 1, article 12456, 2016.

[96] H. Zhang, J. S. Berg, Z. Li et al., “Myosin-X provides a motor-based link between integrins and the cytoskeleton,” *Nature Cell Biology*, vol. 6, no. 6, pp. 523–531, 2004.

[97] K. L. Weber, A. M. Sokac, J. S. Berg, R. E. Cheney, and W. M. Bement, “A microtubule-binding myosin required for nuclear anchoring and spindle assembly,” *Nature*, vol. 431, no. 7006, pp. 325–329, 2004.

[98] S. Almagro, C. Durmорт, A. Chervin-Petinot et al., “The motor protein myosin-X transports VE-cadherin along filopodia to allow the formation of early endothelial cell-cell contacts,” *Molecular and Cellular Biology*, vol. 30, no. 7, pp. 7103–7117, 2010.

[99] M. Horsthemke, A. C. Bachg, K. Groll et al., “Multiple roles of filopodial dynamics in particle capture and phagocytosis and phenotypes of Cdc42 and Myo10 deletion,” *The Journal of Biological Chemistry*, vol. 292, no. 17, pp. 7258–7273, 2017.

[100] H. Tokuo, K. Mabuchi, and M. Ikebe, “The motor activity of myosin-X promotes actin fiber convergence at the cell periphery to initiate filopodia formation,” *The Journal of Cell Biology*, vol. 179, no. 2, pp. 229–238, 2007.

[101] K. He, T. Sakai, Y. Tsukasakii, T. M. Watanabe, and M. Ikebe, “Myosin X is recruited to nascent focal adhesions at the leading edge and induces multi-cycle filopodial elongation,” *Scientific Reports*, vol. 7, no. 1, p. 13685, 2017.
[102] M. L. Gardel, B. Sabass, L. Ji, G. Danuser, U. S. Schwarz, and C. M. Waterman, “Traction stress in focal adhesions correlates biaxially with actin retrograde flow speed,” *The Journal of Cell Biology*, vol. 183, no. 6, pp. 999–1005, 2008.

[103] O. Sato, H. S. Jung, S. Komatsu et al., “Activated full-length myosin-X moves processively on filopodia with large steps toward diverse two-dimensional directions,” *Scientific Reports*, vol. 7, no. 1, article 44237, 2017.

[104] S. Nagy and R. S. Rock, “Structured post-IQ domain governs selectivity of myosin X for fascin-actin bundles,” *The Journal of Biological Chemistry*, vol. 285, no. 34, pp. 26608–26617, 2010.

[105] E. G. Heimsath Jr., Y. I. Yim, M. Mustapha, J. A. Hammer, and R. E. Cheney, “Myosin-X knockout is semi-lethal and demonstrates that myosin-X functions in neural tube closure, pigmentation, hyaloid vasculature regression, and filopodia formation,” *Scientific Reports*, vol. 7, no. 1, article 17354, 2017.

[106] A. C. Bachg, M. Horsthemke, B. V. Skryabin et al., “Phenotypic analysis of Myo10 knockout (Myo10<sup>–/–</sup>) mice lacking full-length (motorized) but not brain-specific headless myosin X,” *Scientific Reports*, vol. 9, no. 1, p. 597, 2019.

[107] Y. Y. Sun, Y. F. Yang, and K. E. Keller, “Myosin-X silencing in the trabecular meshwork suggests a role for tunneling nanotubes in outflow regulation,” *Investigative Ophthalmology & Visual Science*, vol. 60, no. 2, pp. 843–851, 2019.

[108] E. Jash, P. Prasad, N. Kumar, T. Sharma, A. Goldman, and S. Sehrawat, “Perspective on nanochannels as cellular mediators in different disease conditions,” *Cell Communication and Signaling: CCS*, vol. 16, no. 1, p. 76, 2018.

[109] S. Sisakhtnezhad and L. Khosravi, “Emerging physiological and pathological implications of tunneling nanotubes formation between cells,” *European Journal of Cell Biology*, vol. 94, no. 10, pp. 429–443, 2015.

[110] B. Mattes and S. Scholpp, “Emerging role of contact-mediated cell communication in tissue development and diseases,” *Histochemistry and Cell Biology*, vol. 150, no. 5, pp. 431–442, 2018.

[111] P. Sahu, S. R. Jena, and L. Samanta, “Tunneling nanotubes: a versatile target for cancer therapy,” *Current Cancer Drug Targets*, vol. 18, no. 6, pp. 514–521, 2018.

[112] A. Chauveau, A. Archer, P. Eissmann, E. Vivier, and D. M. Davis, “Membrane nanotubes facilitate long-distance interactions between natural killer cells and target cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 12, pp. 5545–5550, 2010.

[113] Y. H. Lee, S. F. Chang, and J. Liaw, “Anti-apoptotic gene delivery with cyclo-(d-Trp-Tyr) peptide nanotube via eye drop following corneal epithelial debridement,” *Pharmaceuticals*, vol. 7, no. 3, pp. 122–136, 2015.

[114] C. Molzer, S. P. Shankar, V. Masalski, M. Griffith, L. Kuffova, and J. V. Forrester, “TGF-β1-activated type 2 dendritic cells promote wound healing and induce fibroblasts to express tenascin C following corneal full-thickness hydrogel transplantation,” *Journal of Tissue Engineering and Regenerative Medicine*, vol. 13, no. 9, pp. 1507–1517, 2019.

[115] A. Calipel, V. Abonnent, O. Nicole et al., “Status of RASSF1A in uveal melanocytes and melanoma cells,” *Molecular Cancer Research*, vol. 9, no. 9, pp. 1187–1198, 2011.

[116] L. van der Weyden and D. J. Adams, “The Ras-association domain family (RASSF) members and their role in human tumourigenesis,” *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*, vol. 1776, no. 1, pp. 58–85, 2007.

[117] L. M. A. Murray and A. D. Krasnodembskaya, “Concise review: intercellular communication via organelle transfer in the biology and therapeutic applications of stem cells,” *Stem Cells*, vol. 37, no. 1, pp. 14–25, 2019.

[118] X. Li, Y. Zhang, S. C. Yeung et al., “Mitochondrial transfer of induced pluripotent stem cell-derived mesenchymal stem cells to airway epithelial cells attenuates cigarette smoke-induced damage,” *American Journal of Respiratory Cell and Molecular Biology*, vol. 51, no. 3, pp. 455–465, 2014.

[119] H. Han, J. Hu, Q. Yan et al., “Bone marrow-derived mesenchymal stem cells rescue injured H9c2 cells via transferring intact mitochondria through tunneling nanotubes in an in vitro simulated ischemia/reperfusion model,” *Molecular Medicine Reports*, vol. 13, no. 2, pp. 1517–1524, 2016.

[120] S. Paliwal, R. Chaudhuri, A. Agrawal, and S. Mohanty, “Regenerative abilities of mesenchymal stem cells through mitochondrial transfer,” *Journal of Biomedical Science*, vol. 25, no. 1, p. 31, 2018.

[121] C. J. Rocca and S. Cherqui, “Potential use of stem cells as a therapy for cystinosis,” *Pediatric Nephrology*, vol. 34, no. 6, pp. 965–973, 2019.

[122] T. V. Johnson and K. R. Martin, “Cell transplantation approaches to retinal ganglion cell neuroprotection in glaucoma,” *Current Opinion in Pharmacology*, vol. 13, no. 1, pp. 78–82, 2013.

[123] J. Alvarado, C. Murphy, and R. Juster, “Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals,” *Ophthalmology*, vol. 91, no. 6, pp. 564–579, 1984.

[124] E. J. Snider, R. T. Vannatta, L. Schildmeyer, W. D. Stamer, and C. R. Ethier, “Characterizing differences between MSCs and TM cells: toward autologous stem cell therapies for the glaucomatous trabecular meshwork,” *Journal of Tissue Engineering and Regenerative Medicine*, vol. 12, no. 3, pp. 695–704, 2018.

[125] D. W. Abu-Hassan, X. Li, E. I. Ryan, T. S. Acott, and M. J. Kelley, “Induced pluripotent stem cells restore function in a human cell loss model of open-angle glaucoma,” *Stem Cells*, vol. 33, no. 3, pp. 751–761, 2015.

[126] Y. Du, D. S. Roh, M. M. Mann, M. L. Funderburk, J. L. Funderburk, and J. S. Schuman, “Multipotent stem cells from trabecular meshwork become phagocytic TM cells,” *Investigative Ophthalmology & Visual Science*, vol. 53, no. 3, pp. 1566–1575, 2012.

[127] W. Zhu, A. Jain, O. W. Gramlich, B. A. Tucker, V. C. Sheffer, and M. H. Kuehn, “Restoration of aqueous humor outflow following transplantation of iPSC-derived trabecular meshwork cells in a transgenic mouse model of glaucoma,” *Investigative Ophthalmology & Visual Science*, vol. 58, no. 4, pp. 2054–2062, 2017.

[128] T. P. Stryjewski, J. A. Stefater, and D. Elliott, “Pharmacetical formulation methods for improving retinal drug delivery,” *Seminars in Ophthalmology*, vol. 34, no. 4, pp. 218–222, 2019.

[129] C. H. Tsai, P. Y. Wang, I. C. Lin, H. Huang, G. S. Liu, and C. L. Tseng, “Ocular drug delivery: role of degradable polymeric nanocarriers for ophthalmic application,” *International Journal of Molecular Sciences*, vol. 19, no. 9, p. 2830, 2018.
[130] D. R. Janagam, L. Wu, and T. L. Lowe, "Nanoparticles for drug delivery to the anterior segment of the eye," *Advanced Drug Delivery Reviews*, vol. 122, pp. 31–64, 2017.

[131] R. D. Bachu, P. Chowdhury, Z. H. F. Al-Saedi, P. K. Karla, and S. H. S. Boddu, "Ocular drug delivery barriers-role of nanocarriers in the treatment of anterior segment ocular diseases," *Pharmaceutics*, vol. 10, no. 1, p. 28, 2018.

[132] H. Y. Zhou, J. L. Hao, S. Wang, Y. Zheng, and W. S. Zhang, "Nanoparticles in the ocular drug delivery," *International Journal of Ophthalmology*, vol. 6, no. 3, pp. 390–396, 2013.

[133] R. Singh and H. S. Nalwa, "Medical applications of nanoparticles in biological imaging, cell labeling, antimicrobial agents, and anticancer nanodrugs," *Journal of Biomedical Nanotechnology*, vol. 7, no. 4, pp. 489–503, 2011.

[134] S. Ferrati, S. Shamsudeen, H. D. Summers et al., "Inter-endothelial transport of microvectors using cellular shuttles and tunneling nanotubes," *Small*, vol. 8, no. 20, pp. 3151–3160, 2012.

[135] S. Russell, J. Bennett, J. A. Wellman et al., "Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open- label, phase 3 trial," *The Lancet*, vol. 390, no. 10097, pp. 849–860, 2017.

[136] H. R. Chinnery, C. M. Leong, W. Chen, J. V. Forrester, and P. G. McMenamin, "TLR9 and TLR7/8 activation induces formation of keratic precipitates and giant macrophages in the mouse cornea," *Journal of Leukocyte Biology*, vol. 97, no. 1, pp. 103–110, 2015.
